No abstract

Background: To date there has been no randomised controlled trial demonstrating the safety and efficacy of macular relocation surgery (MRS) for age related macular degeneration (AMD). Vision can be improved in some patients and made worse in others despite successful surgery or because of complications. Purpose: To determine which patients would benefit from MRS. Methods: Twenty nine patients with exudative AMD took part in a prospective, non-comparative, interventional study. Macular relocation surgery involved phacoemulsification, vitrectomy, 360˚retinotomy, excision of choroidal neovascular membrane, and macular relocation using an infusion of 5-fluorouracil and low molecular weight heparin as adjuvant to prevent proliferative vitreoretinopathy. Patients underwent protocol refraction preoperatively and six-monthly postoperatively by designated optometrists. Preoperative fundus fluorescein angiograms were read by masked observers and the lesions were classified according to a set protocol. The main outcome measures were visual improvement, final vision of better than 20/400, reading speed, critical print size. Logistic and multiple stepwise linear regressions were used to identify independent factors which predicted the main outcomes. Results: Preoperative visual acuity (20/120 or worse) and lesion type (predominantly classic or submacular haemorrhage) were significantly associated with visual improvement (coefficient of regression B = 26.8, p,0.001 and B = 14.9 with p = 0.045 respectively). There were no significant independent factors which predicted a final distance logMAR visual acuity of 1.3 (20/400) or any arbitrary definition of blindness. Conclusions: The study showed that it was possible to select cases that were more likely to experience an improvement in vision following MRS.

Key Points Question What is the topographic distribution of retinal neovascularization in patients with proliferative diabetic retinopathy, and is there an association between response to treatment and the retinal location of the neovascularization? Findings In this post hoc unmasked analysis of the Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy (CLARITY) randomized clinical trial, treatment-naive retinal neovascularization elsewhere (NVE) had a predilection for the nasal quadrant. By 52 weeks, the aflibercept group was more likely to have regression of NVE; neither treatment was likely to be associated with complete regression of disc neovascularization (NVD). Meaning This study further elaborates on the outcomes of the CLARITY trial in that, anatomically, despite the superior outcomes among patients within NVE who received aflibercept, regression was seen more in NVE than in NVD.

PDT delivered in clinical practice is at least as effective as that reported in randomised clinical trials and uses fewer treatments.

Based on OCT3 findings, eyes with AMD treated with PDT have a thinner fibrous scar and better preserved retinal thickness when compared with untreated fellow eyes with end-stage fibrotic scarring.